GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARS Pharmaceuticals Inc (NAS:SPRY) » Definitions » Price-to-Free-Cash-Flow

SPRY (ARS Pharmaceuticals) Price-to-Free-Cash-Flow : 262.64 (As of Apr. 30, 2025)


View and export this data going back to 2022. Start your Free Trial

What is ARS Pharmaceuticals Price-to-Free-Cash-Flow?

As of today (2025-04-30), ARS Pharmaceuticals's share price is $13.92. ARS Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.05. Hence, ARS Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is 262.64.

The historical rank and industry rank for ARS Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

SPRY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 197.74   Med: 234.44   Max: 280.75
Current: 262.63

During the past 5 years, ARS Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 280.75. The lowest was 197.74. And the median was 234.44.

SPRY's Price-to-Free-Cash-Flow is ranked worse than
92.17% of 217 companies
in the Biotechnology industry
Industry Median: 28 vs SPRY: 262.63

ARS Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2024 was $0.35. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.05.


ARS Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for ARS Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARS Pharmaceuticals Price-to-Free-Cash-Flow Chart

ARS Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
- - - - 83.07

ARS Pharmaceuticals Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 83.07

Competitive Comparison of ARS Pharmaceuticals's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, ARS Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARS Pharmaceuticals's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ARS Pharmaceuticals's Price-to-Free-Cash-Flow falls into.


;
;

ARS Pharmaceuticals Price-to-Free-Cash-Flow Calculation

ARS Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=13.92/0.053
=262.64

ARS Pharmaceuticals's Share Price of today is $13.92.
ARS Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

ARS Pharmaceuticals  (NAS:SPRY) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


ARS Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ARS Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ARS Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
11682 El Camino Real, Suite 120, San Diego, CA, USA, 92130
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Executives
Laura Shawver director, officer: Chief Executive Officer 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Eric Karas officer: Chief Commercial Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Richard E Lowenthal director, 10 percent owner, officer: President and CEO 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Sarina Tanimoto 10 percent owner, officer: Chief Medical Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma officer: Chief Business Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Brian Dorsey officer: Chief Operating Officer C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
James E Flynn director, 10 percent owner, other: Director by deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Kathleen D. Scott officer: Chief Financial Officer C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander A Fitzpatrick officer: Chief Legal Officer 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Orbimed Capital Gp Vi Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rajeev Dadoo director C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Michael Kelly director C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130